Loading
A phase 1/2 trial of REC-7735 run by Recursion Pharmaceuticals Inc., now recruiting.
REC-7735 in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07819136 by Recursion Pharmaceuticals Inc., with 90 participants planned, started 2026-09. Conditions recorded: Solid Tumors. Interventions recorded: REC-7735.
Shares Recursion Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Recursion Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Recursion Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/